Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease.

Mukaetova-Ladinska EB, Garcia-Siera F, Hurt J, Gertz HJ, Xuereb JH, Hills R, Brayne C, Huppert FA, Paykel ES, McGee M, Jakes R, Honer WG, Harrington CR, Wischik CM.

Am J Pathol. 2000 Aug;157(2):623-36.

2.

Lewy body variant of Alzheimer's disease: selective neocortical loss of t-SNARE proteins and loss of MAP2 and alpha-synuclein in medial temporal lobe.

Mukaetova-Ladinska EB, Xuereb JH, Garcia-Sierra F, Hurt J, Gertz HJ, Hills R, Brayne C, Huppert FA, Paykel ES, McGee MA, Jakes R, Honer WG, Harrington CR, Wischik CM.

ScientificWorldJournal. 2009 Dec 16;9:1463-75. doi: 10.1100/tsw.2009.151.

3.

Reduced Reelin expression accelerates amyloid-beta plaque formation and tau pathology in transgenic Alzheimer's disease mice.

Kocherhans S, Madhusudan A, Doehner J, Breu KS, Nitsch RM, Fritschy JM, Knuesel I.

J Neurosci. 2010 Jul 7;30(27):9228-40. doi: 10.1523/JNEUROSCI.0418-10.2010.

4.

Progression of neurofibrillary changes and PHF-tau in end-stage Alzheimer's disease is different from plaque and cortical microglial pathology.

Thal DR, Arendt T, Waldmann G, Holzer M, Zedlick D, Rüb U, Schober R.

Neurobiol Aging. 1998 Nov-Dec;19(6):517-25.

PMID:
10192210
5.

Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid.

Culvenor JG, McLean CA, Cutt S, Campbell BC, Maher F, Jäkälä P, Hartmann T, Beyreuther K, Masters CL, Li QX.

Am J Pathol. 1999 Oct;155(4):1173-81.

7.

Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease.

Rijal Upadhaya A, Kosterin I, Kumar S, von Arnim CA, Yamaguchi H, Fändrich M, Walter J, Thal DR.

Brain. 2014 Mar;137(Pt 3):887-903. doi: 10.1093/brain/awt362. Epub 2014 Feb 10.

PMID:
24519982
8.

A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model.

Hurtado DE, Molina-Porcel L, Iba M, Aboagye AK, Paul SM, Trojanowski JQ, Lee VM.

Am J Pathol. 2010 Oct;177(4):1977-88. doi: 10.2353/ajpath.2010.100346. Epub 2010 Aug 27.

9.

Neocortical and hippocampal amyloid-β and tau measures associate with dementia in the oldest-old.

Robinson JL, Geser F, Corrada MM, Berlau DJ, Arnold SE, Lee VM, Kawas CH, Trojanowski JQ.

Brain. 2011 Dec;134(Pt 12):3708-15. doi: 10.1093/brain/awr308. Epub 2011 Nov 26.

10.

Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins.

Pham E, Crews L, Ubhi K, Hansen L, Adame A, Cartier A, Salmon D, Galasko D, Michael S, Savas JN, Yates JR, Glabe C, Masliah E.

FEBS J. 2010 Jul;277(14):3051-67. doi: 10.1111/j.1742-4658.2010.07719.x. Epub 2010 Jun 22.

11.

Enhanced Tau Aggregation in the Presence of Amyloid β.

Bennett RE, DeVos SL, Dujardin S, Corjuc B, Gor R, Gonzalez J, Roe AD, Frosch MP, Pitstick R, Carlson GA, Hyman BT.

Am J Pathol. 2017 Jul;187(7):1601-1612. doi: 10.1016/j.ajpath.2017.03.011. Epub 2017 May 10.

PMID:
28500862
12.

Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.

Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J.

Am J Pathol. 1999 Sep;155(3):853-62.

13.

[Alzheimer's disease: lesions and their progression].

Duyckaerts C, Colle MA, Delatour B, Hauw JJ.

Rev Neurol (Paris). 1999;155 Suppl 4:S17-27. Review. French.

PMID:
10637934
14.

[Expression of proteins related neurodegeneration in autopsy brains of the aged].

Zhu M, Meng X, Wang L, Hu Y, Zhang H, Han Z.

Zhonghua Bing Li Xue Za Zhi. 2014 Oct;43(10):651-6. Chinese.

PMID:
25567589
15.

Olfactory tau pathology in Alzheimer disease and mild cognitive impairment.

Attems J, Jellinger KA.

Clin Neuropathol. 2006 Nov-Dec;25(6):265-71.

PMID:
17140156
16.

Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease.

Suh YH, Checler F.

Pharmacol Rev. 2002 Sep;54(3):469-525. Review. Erratum in: Pharmacol Rev. 2006 Jun;58(2):280.

17.

Abeta-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with Abeta pathology.

Fukami S, Watanabe K, Iwata N, Haraoka J, Lu B, Gerard NP, Gerard C, Fraser P, Westaway D, St George-Hyslop P, Saido TC.

Neurosci Res. 2002 May;43(1):39-56.

PMID:
12074840
18.

Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease.

Bossers K, Wirz KT, Meerhoff GF, Essing AH, van Dongen JW, Houba P, Kruse CG, Verhaagen J, Swaab DF.

Brain. 2010 Dec;133(Pt 12):3699-723. doi: 10.1093/brain/awq258. Epub 2010 Oct 1.

PMID:
20889584
19.

Olfactory involvement in aging and Alzheimer's disease: an autopsy study.

Attems J, Lintner F, Jellinger KA.

J Alzheimers Dis. 2005 Apr;7(2):149-57; discussion 173-80.

PMID:
15851853
20.

Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain.

Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET, Frosch MP, Albert MS, Hyman BT, Irizarry MC.

Neurology. 2004 Mar 23;62(6):925-31.

PMID:
15037694

Supplemental Content

Support Center